2022-2023 EVENTS

2022 Events

28 Aug - 01 Sep 2022
The International Surgical Week (ISW)
Kuala Lumpur

31 Aug – 2 Sept 2022
Medical Fair Asia
Marina Bay Sands, Singapore

3-9 September
Medical Fair Asia
Digital, Online

9-10 September 2022
World Pediatrics Conference
Bangkok, Thailand

9-10 September 2022
World Heart and Cardiothoracic Surgery Conference
Bangkok, Thailand

19-21 September 2022
23rd SE-Asian Healthcare & Pharma Show
Kuala Lumpur

27-29 September 2022
Smart Healthcare Expo (Health Malaysia)

27-29 September 2022
Asia Pandemic Congress
Kuala Lumpur Convention Centre

19-20 September 2022
23nd Global Nursing Education Conference
Brisbane, Australia

30 Sep - 2 Oct 2022
Malaysia International Dental Show (MIDS)
Sunway Pyramid Convention Centre, Subang Jaya, Malaysia

7-9 November 2022
Saudi International MedLab Expo
Riyadh International Convention and Exhibition Center

7-9 November 2022
Saudi International Pharma Expo
Riyadh International Convention and Exhibition Center

11-13 November 2022
Eldercare Exhibition and Conference Asia (ELDEX Asia 2022)
Suntex Singapore Exhibition and Convention Centre

14-15 November 2022
Healthcare Asia Pacific
Osaka, Japan

2023 Events

30 May – 1 June 2023
KL Convention Centre, Kuala Lumpur

13-15 September 2023
Medical Fair Thailand
BITEC, Bangkok

Free counters!

WHO recognises a Malaysian-developed hepatitis C medication as necessary drug

The World Health Organization (WHO) has placed a hepatitis C medication partially developed in Malaysia to its list of essential medicines (EML).

For the treatment of chronic adult hepatitis C virus infection, the WHO approved the use of ravidasvir in combination with sofosbuvir as a direct-acting antiviral.

According to Free Malaysia Today (FMT), blood is used in the transmission of hepatitis C. It can develop into liver cirrhosis, scarring, and ultimately cancer if left untreated.

Tan Sri Dr Noor Hisham Abdullah, a former director-general of health, claimed that Malaysia initiated the push to include the medicine.

“The ravidasvir listing on the WHO EML is another milestone for Malaysia in its journey of developing a cost-effective hepatitis C drug. It addresses healthcare access, affordability and equity, particularly in low- and middle-income countries.”

“This addition to the list would mean many more member states and civil society groups can gain access to this affordable medicine and eliminate hepatitis C by 2030,” said Dr Noor Hisham, now a board member of DNDi was quoted saying by the news portal.

This global, non-profit research and development group, DNDi stands for Drugs for Neglected Diseases Initiative.

Initiated by the health ministry of Malaysia and DNDi, the development of ravidasvir also involved the health ministry of Thailand, Médecins Sans Frontières, Presidio Pharmaceuticals, Pharco Pharmaceuticals, and Pharmaniaga Berhad.

Additionally, in June 2021, Malaysia approved the use of ravidasvir hydrochloride.

The first very successful hepatitis C medicine, sofosbuvir, used to cost more than RM300,000 for a 12-week treatment, making the listing historically significant for Malaysia and the rest of the world.

It was also reported that the medicine was unavailable to Malaysian patients since importing it would have been too expensive, therefore the health ministry had to look into alternative treatment options.

It started collaborating with DNDi in 2016, which sparked the creation of the ravidasvir-sofosbuvir therapy.

At the same time, the ministry was able to combine the usage of daclatasvir and a generic form of sofosbuvir that was available from Egypt at a significantly reduced price.

The news report further said three years before the sofosbuvir-ravidasvir combo medicine treatment, the procedure was made available at public hospitals in March 2018.

The amended EML lists, which had previously contained ravidasvir (in conjunction with sofosbuvir), were created with the intention of facilitating increased access to cutting-edge medications with obvious therapeutic benefits.

Without endangering the finances of low- and middle-income countries, these medicines could have a significant worldwide influence on public health.

“We do what is right for the people,“ Dr Noor Hisham remarked. It is satisfying to contribute to improving healthcare.

This, he continued, was Malaysia’s contribution to World Hepatitis Day in 2023.

According to WHO director-general Dr. Tedros Adhanom Ghebreyesus, the WHO EML has served as a comprehensive, evidence-based resource for the most significant medications with the potential to have the greatest positive impact on health for more than 40 years.

“All countries currently face growing difficulties in guaranteeing consistent and fair access to many quality-assured vital medicines due to rising pricing and supply chain interruptions.”

He declared last week that “WHO is committed to supporting all countries to overcome these obstacles to increase access with equity.” – The Sun Daily